Top 50 Biotech Startup Investors in Asia (September 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Qiming Venture Partners
VC Fund
|
93 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $4.3M–$120M |
|
HSG
VC Fund
|
54 | China, United States, Australia | Series B, Series A, Seed | Artificial Intelligence, Biotechnology, Software | $2M–$226M |
|
BioVenture
VC Fund
|
43 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $4.4M–$73M |
|
Lilly Asia Ventures
VC Fund
|
37 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $14M–$308M |
|
Matrix Partners China
VC Fund
|
36 | China, United States, Singapore | Series A, Series B, Seed | Health Care, Software, Biotechnology | $1.5M–$141M |
|
Kaitai Capital
VC Fund
|
33 | China, United States, Singapore | Series A, Seed, Series B | Biotechnology, Health Care, Pharmaceutical | $1.4M–$57M |
|
Med-Fine Capital
VC Fund
|
31 | China, Hong Kong, United States | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $3M–$60M |
|
Frees Fund
VC Fund
|
30 | China, United States, Singapore | Series A, Seed, Angel | Artificial Intelligence, Health Care, Biotechnology | $447k–$28M |
|
Legend Capital
VC Fund
|
30 | China, United States, South Korea | Series B, Series A, Series C | Health Care, Medical, Biotechnology | $2.4M–$200M |
|
IDG Capital
VC Fund
|
29 | China, United States, India | Series A, Series B, Series C | Software, Internet, E-Commerce | $2.6M–$354M |
|
Mitsubishi UFJ Capital
VC Fund
|
29 | Japan, United States, Singapore | Series A, Series B | Information Technology, Software, Health Care | $1.2M–$38M |
|
Seeds Capital
VC Fund
|
27 | Singapore, United States, Hong Kong | Seed, Series A, Series B | Biotechnology, Artificial Intelligence, Health Care | $767k–$45M |
|
Northern Light Venture Capital
VC Fund
|
26 | China, United States, South Korea | Series A, Series B, Venture - Series Unknown | Health Care, Medical, Biotechnology | $1.5M–$58M |
|
SMBC Venture Capital
VC Fund
|
26 | Japan, United States, Singapore | Series A, Series B | Information Technology, Software, Health Care | $1.2M–$51M |
|
UntroD Capital
VC Fund
|
22 | Japan, Singapore, Austria | Seed, Venture - Series Unknown, Series A | Manufacturing, Biotechnology, Health Care | $316k–$15M |
|
Longpan Investment
VC Fund
|
22 | China, United States, Cayman Islands | Series A, Seed, Series B | Health Care, Medical, Biotechnology | $14M–$60M |
|
Sherpa Healthcare Partners
VC Fund
|
22 | China, United States, Kenya | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7.2M–$128M |
|
Shenzhen Capital Group
VC Fund
|
21 | China, United States, Japan | Series A, Series B, Series C | Manufacturing, Health Care, Software | $1.5M–$156M |
|
ANRI
VC Fund
|
21 | Japan, United States, Indonesia | Seed, Series A, Venture - Series Unknown | Software, Health Care, Information Technology | $268k–$41M |
|
Linear Capital
VC Fund
|
21 | China, Singapore, Switzerland | Seed, Angel, Series A | Artificial Intelligence, Software, Manufacturing | $1.4M–$122M |
|
CDH Investments
VC Fund
|
20 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $7.1M–$220M |
|
Highlight Capital
VC Fund
|
20 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $3M–$84M |
|
Gaorong Capital
VC Fund
|
19 | China, United States, Hong Kong | Series A, Series B, Seed | Information Technology, Software, Artificial Intelligence | $1.6M–$120M |
|
Green Pine Capital Partners
VC Fund
|
19 | China, United States, Canada | Series A, Angel, Series B | Artificial Intelligence, Software, Biotechnology | $425k–$150M |
|
Osaka University Venture Capital
VC Fund
|
19 | Japan | Seed, Venture - Series Unknown, Series A | Biotechnology, Health Care, Medical | $480k–$17M |
|
Fast Track Initiative, Inc.
VC Fund
|
19 | Japan, United States, United Kingdom | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $345k–$117M |
|
Addor Capital
VC Fund
|
18 | China, Hong Kong, Singapore | Series A, Series B, Seed | Manufacturing, Semiconductor, Electronics | $1.4k–$48M |
|
TF Capital
VC Fund
|
18 | China, United States | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7M–$1.4B |
|
ZhenFund
VC Fund
|
18 | China, United States, Singapore | Seed, Series A, Angel | Artificial Intelligence, Software, E-Commerce | $150k–$23M |
|
Puhua Capital
VC Fund
|
18 | China, United Kingdom, United States | Series A, Series B, Seed | Health Care, Medical, Manufacturing | $1.5M–$103M |
|
Hillhouse Investment
VC Fund
|
18 | China, United States, Singapore | Series B, Series A, Series C | Biotechnology, Health Care, Software | $2.9M–$230M |
|
Delian Capital
VC Fund
|
17 | China, United States, France | Series A, Seed, Series B | Biotechnology, Manufacturing, Health Care | $1.5M–$50M |
|
Pan-Lin Capital
VC Fund
|
17 | China, United States, Canada | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $1.4k–$58M |
|
Cowin Capital
VC Fund
|
17 | China, Hong Kong, United States | Series A, Series B, Seed | Manufacturing, Health Care, Biotechnology | $1.4M–$76M |
|
UTEC - The University of Tokyo Edge Capital Partners
VC Fund
|
16 | Japan, United States, India | Seed, Series A, Series B | Health Care, Biotechnology, Medical | $900k–$20M |
|
Prox Ventures
VC Fund
|
16 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $2.5M–$28M |
|
Beijing Huafang Investment
VC Fund
|
15 | China | Series A, Seed, Angel | Biotechnology, Medical, Biopharma | $13M–$30M |
|
Oriental Fortune Capital
VC Fund
|
15 | China, United States | Series A, Series B, Seed | Software, Manufacturing, Information Technology | $1.4M–$100M |
|
CD Capital
VC Fund
|
15 | China, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical Device | $1.4M–$34M |
|
Legend Star
VC Fund
|
15 | China, United States, France | Series A, Seed, Angel | Health Care, Medical, Robotics | $425k–$52M |
|
Keio Innovation Initiative
VC Fund
|
14 | Japan, United Kingdom | Series A, Seed, Venture - Series Unknown | Health Care, Medical, Biotechnology | $826k–$41M |
|
Mizuho Capital
VC Fund
|
14 | Japan, United States, Singapore | Series A, Venture - Series Unknown, Series B | Information Technology, Software, Artificial Intelligence | $661k–$47M |
|
K2VC
VC Fund
|
14 | China, United States, Hong Kong | Series A, Angel, Seed | E-Commerce, Manufacturing, Software | $356k–$38M |
|
Baidu Ventures
VC Fund
|
14 | China, United States, Singapore | Series A, Seed, Series B | Artificial Intelligence, Health Care, Biotechnology | $1.5M–$123M |
|
Shunwei Capital
VC Fund
|
14 | China, United States, India | Series A, Series B, Series C | Manufacturing, Software, Internet | $1.5M–$105M |
|
JAFCO
VC Fund
|
14 | Japan, United States, Israel | Series A, Series B, Venture - Series Unknown | Information Technology, Software, Artificial Intelligence | $1.3M–$71M |
|
BioTrack Capital
VC Fund
|
14 | China, United States, Singapore | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $14M–$168M |
|
Hillhouse Ventures
VC Fund
|
14 | China, Singapore, Norway | Series A, Series B, Seed | Manufacturing, Biotechnology, Health Care | $10M–$120M |
|
SDIC Venture Capital
VC Fund
|
14 | China, United States, Hong Kong | Series B, Series A, Series C | Manufacturing, Biotechnology, Electronics | $2.8M–$129M |
|
Taiyu Investment
VC Fund
|
14 | China | Seed, Series A, Angel | Medical, Health Care, Biotechnology | $4.1M–$29M |
| Access all 50 investors in Asia Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 1160
- Round size: Series A $4.3M–$50M; Series B $8M–$89M; Series C $12M–$120M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely actively investing — fresh fund, raised $8M in 2026
Portfolio highlights
- LP Amina — LP Amina focuses on products that improve coal-fired power plant's emissions and efficiency. Leveraging 50 unique patented products to improve the firing system of a coal-fired boiler, including Rotating Vane Wheels, High Performance Classifiers, Coal Pipe Balancing Technologies, and Burner Enhancements, the Company provides products andsolutions that will meet or exceed the expectations of their customers. Furthermore, LP Amina's corporate culture is one of a relentless pursuit of continuous improvement. Utilizing the latest technology and traditional know-how from the World's two largest users of Coal for power generation, the Company is well positioned to develop new products and solutions to meet the ever changing needs of Power Industry.LP Amina's staff has over 20 years of experience in the design, fabrication, installation and commissioning of coal-fired power plants. During this time, the team has gained a wide range of experience from the evolution of the US Power Market. Increases in environmental regulations and free market driven energy prices have forced plant operators to reduce emissions and improve reliability while lowering operational cost. LP Amina's engineering and design team will leverage this experience gained from the US and Europe to address the emergence of similar issues in China.
- Nice Tuan — Nice Tuan is an e-commerce platform that provides daily groceries and miscellaneous products.
- Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
HSG is a leading venture capital and private equity firm investing globally in the technology, healthcare, and consumer sectors.
Show more...Investment focus
- Industry: Artificial Intelligence, Biotechnology, Software
- Stage:Series B, Series A, Seed
- Geography: China, United States, Australia
Investor stats
- Total investments: 1019
- Round size: Seed $2M–$50M; Series A $3.1M–$100M; Series B $11M–$226M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely still investing — raised $2.5B in 2024
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- Hypershell — An exoskeleton innovator reshaping lifestyles and enabling technology to empower life.
- Suisheng Technology — Suisheng Technology is an innovative company specializing in AI-driven memory services, dedicated to developing intelligent solutions that help individuals and businesses capture, organize, and retrieve important information with greater efficiency and precision.
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 191
- Round size: Seed $7.9M–$41M; Series A $4.4M–$47M; Series B $7.1M–$73M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $204M in 2016
Portfolio highlights
- AusperBio — AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
- Inno Medicine — Inno Pharmaceutical Technology specializes in research on the pathogenesis of atherosclerosis. The company focuses on the development of targeted nanoliposomes, targeting molecules with independent intellectual property rights, and currently focuses on the plaque reversal treatment of atherosclerosis.
- MyoGene Life Sciences — MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 248
- Round size: Series A $14M–$100M; Series B $25M–$110M; Series C $30M–$308M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
- InventisBio — InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
- Abogen Biosciences — Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.
Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 667
- Round size: Seed $1.5M–$74M; Series A $2.9M–$56M; Series B $10M–$141M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely still investing — raised $92M in 2023
Portfolio highlights
- Lexin — LexinFintech Holdings is an online consumer finance platform for educated young adults in China. As one of China's leading financial technology companies, Lexin integrates its e-commerce-driven installment finance platform, Fenqile, with advanced risk management technologies, the Company's Dingsheng online investment platform, and theCompany's Juzi Licai online investment platform for individual investors, to create a comprehensive consumer finance ecosystem. The Company utilizes technologies including big data, cloud computing and artificial intelligence to enable the near-instantaneous matching of user funding requests with offers from the Company's more than 30 funding partners, which include commercial banks, consumer finance companies, and other licensed financial institutions. By serving the credit needs of China's educated young adults, Lexin helps its more than 20 million registered users to enjoy a better quality of life through the use of better credit.
- Camera360 — Camera360 is a professional but easy-to use App for photo editing and selfie retouching. Tag #camera360
- Liepin — Liepin is the largest and most professional high-end talent community-based recruitment site, with its innovative products and unique service model model for create an interactive high-end talent recruitment platform between business, headhunting and workplace. Tens of thousands of professional executive search consultant for businesses and jobseekers set up communication between the bridge and accelerate corporate recruitment process, recommended paying jobs in the workplace, career development planning. 16 job seekers to avoid the risk of privacy protection, millions of high-end elite member libraries, help enterprises development needs.
KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Singapore
Investor stats
- Total investments: 160
- Round size: Seed $1.4M–$20M; Series A $1.5M–$35M; Series B $10M–$57M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- PaXini Tech — All Scenario Application—Haptic Digitization and Tactile Technology
- Yushi Space — Yushi Space is a liquid rocket developer that focuses on the development and manufacture of large-capacity, low-cost and rapidly reusable liquid rockets.
- Guoke Optoelectronics — Guoke Optoelectronics is a national high-tech enterprise integrating comprehensive capabilities in materials processing, chip design, integrated packaging, optoelectronic devices, application algorithms, and system integration. With the mission of "lighting the way for our peers," Guoke Optoelectronics is committed to becoming a globallyleading company in silicon photonics chip technology and overall solutions
Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 83
- Round size: Seed $8M–$60M; Series A $3M–$40M; Series B $12M–$60M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $73M in 2019
Portfolio highlights
- Zhuanma Biotech — Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."
- Tianyikang Biotechnology — Tianyikang Biotechnology focuses on medical research and the development and application of next-generation cell immunotherapy products.
- Beijing Ansong Technology — Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing.
By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stagestartups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 234
- Round size: Seed $1.4M–$14M; Angel $447k–$14M; Series A $1.5M–$28M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $144M in 2015
Portfolio highlights
- Chuguang 3D — Chuguang 3D is a optical micro-nano 3D sensor technology platform that focuses on research and development, and manufacturing of micro-nano-level optical three-dimensional sensing and measurement and testing instruments.
- Flysound — Flysound is a hearing technology company focused on making advanced AI-powered hearing aids affordable and accessible. Its products combine AI sound processing, Bluetooth connectivity, app-based personalization, and rechargeable convenience. With a focus on innovation, quality, and user-friendly design, Flysound aims to help people hear moreclearly and stay connected to everyday life.
- Yanming Biology — Pyrotech pharmaceuticals is a biotechnology company that focuses om development for drugs for the treatment of inflammation and tumors.
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, South Korea
Investor stats
- Total investments: 499
- Round size: Series A $2.4M–$93M; Series B $12M–$107M; Series C $15M–$200M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — raised $177M in 2021
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- Huixin Bio — Huixin Bio is a developer of exosome purification products and early cancer detection technology.
- NeuShen Therapeutics — We are a global biotech company committed to developing new and effective therapies for psychiatric and neurological disorders affecting millions of patients in need.
IDG Capital is a global investment firm partnering with founders to build enduring businesses through capital, expertise, and long-term support.
Show more...Investment focus
- Industry: Software, Internet, E-Commerce
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 1127
- Round size: Series A $2.6M–$100M; Series B $7M–$112M; Series C $15M–$354M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- AIxCrypto — Qualigen is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as the expansion of its flagship FastPack® diagnostic platform.
- Hypershell — An exoskeleton innovator reshaping lifestyles and enabling technology to empower life.
- Bivision — Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Mitsubishi UFJ Capital is a venture capital firm focusing on life science, ICT, and high technology investments.
Show more...Investment focus
- Industry: Information Technology, Software, Health Care
- Stage:Series A, Series B
- Geography: Japan, United States, Singapore
Investor stats
- Total investments: 668
- Round size: Series A $1.2M–$29M; Series B $3.5M–$38M
- Lead/follow: 9% lead, 91% follow
- Last fund: May invest from a new fund soon — raised $94M in 2020
Portfolio highlights
- ADiXi — Adixi is a tech-driven business that supports the idea that people and technology may work together. It strives to open doors by utilizing cutting-edge technology, such as artificial intelligence, to promote long-term, sustainable corporate and societal progress.
- Caguuu — Caguuu offers high-quality designer furniture at affordable prices, through e-commerce, eliminating middlemen and store operating costs.
- Luxna Biotech — Luxana Biotech is a biotechnology firm dedicated to promoting the practical use of safe and effective nucleic acid therapies. Utilizing nucleic acid chemistry technology, the company strives to provide nucleic acid medicines to patients suffering from diseases that currently lack effective treatments.
Catalysing smart monies into Singapore-based, early-stage technology startups.
Show more...Investment focus
- Industry: Biotechnology, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Series B
- Geography: Singapore, United States, Hong Kong
Investor stats
- Total investments: 148
- Round size: Seed $767k–$6M; Series A $2.4M–$21M; Series B $5M–$45M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- N&E Innovations — Our Kitchen solutions include our heavy duty countertop laminates and surface spray coatings that provide a 90-day long protection that is effective against
- ChemT Biotechnology — The goal of ChemT Biotechnology is to increase patient access to the most cutting-edge biologics, beginning with the urgent issues in manufacturing and research and development.
- Protuoso Biosciences — Protuoso Bio is a pioneering biotechnology company developing Next-Gen MUXBODIES for Complex Diseases. We leverage AI-driven protein engineering and synthetic biology to advance innovative oncology drug research.
Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: China, United States, South Korea
Investor stats
- Total investments: 385
- Round size: Series A $2.9M–$40M; Series B $10M–$58M; Venture - Series Unknown $1.5M–$2.9M
- Lead/follow: 26% lead, 74% follow
- Last fund: Likely still investing — raised $375M in 2021
Portfolio highlights
- Flytech — Flytech specializes in crystal materials and related components for magneto-optical-electrical integrated signal processing.
- Moge Microflow — Moge Microflow is a manufacturer of equipment for microreactors. It provides continuous flow production technologies and equipment for nanomaterials, pharmaceutical intermediates, and fine chemicals, as well as standardized high-end microreactor equipment.
- Bianzhong New Materials — Bianzhong New Materials is a high-tech company that specializes in the research and development of equipment for weaving and shaping three-dimensional preforms of high-strength fiber composite materials.
Sumitomo Mitsui Banking Corporation (SMBC) and its group companies offer a broad range of financial services centered on banking. They are also engaged in the leasing, securities, credit card, investment, mortgage securitization, venture capital and other credit related businesses. The following lists the activities of SMBC, its subsidiaries andaffiliates in the various business segments.
Show more...Investment focus
- Industry: Information Technology, Software, Health Care
- Stage:Series A, Series B
- Geography: Japan, United States, Singapore
Investor stats
- Total investments: 652
- Round size: Series A $1.2M–$51M; Series B $2.3M–$40M
- Lead/follow: 4% lead, 96% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Etaily — Etaily provides e-commerce and retail solutions in the Philippines, enabling brands with end-to-end services, from store management to fulfillment.
- Fermelanta — Fermelanta produces rare plant-based ingredients through microbial fermentation. It engineers a cell to build a biosynthetic pathway of target molecules with gene transfer and disruption.
- Josan-shes — Josan shes is web start up that offers nursing service to women and babies.
UntroD Capital is an R&D-based innovative technology that specializes in social implementation.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Health Care
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Japan, Singapore, Austria
Investor stats
- Total investments: 145
- Round size: Seed $316k–$6M; Series A $2.1M–$15M; Venture - Series Unknown $451k–$10M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- Eco-Pork — Eco-Pork is a co-creation solution farm that supports farmers' food productivity improvement. It is connecting the pig and technology, pork ( Pork ) new business ecosystems ( Ecosystem By building a), in the pork growing demand around the world, to get the most out of the food supply capacity is finite.
- Teragen Energy — Teragen Energy develops an energy technology platform based on advanced regenerative solid oxide fuel cells that provide both power generation and energy storage in a single system. The company’s systems generate electricity from external fuels such as natural gas or hydrogen without combustion and can operate in reverse to store power as hydrogen.Teragen designs modular systems that can be scaled from megawatt-scale installations for data centers to deployments for microgrids, renewable projects, and utilities. Its technology is intended to help operators manage variable renewable output, ride through outages, and address daily capacity needs using one device. Teragen focuses on applications including AI and cloud data centers, manufacturing and cold storage facilities, remote communities, and electric grid infrastructure. The platform is positioned to replace separate diesel generators and battery systems by combining fuel-flexible generation and low-cost storage in a compact footprint.
- IGrid Solutions — IGrid Solutions will promote “eDCM” to optimize power energy demand.
Longpan Investment is an investment firm.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, United States, Cayman Islands
Investor stats
- Total investments: 44
- Round size: Seed $14M–$60M; Series A $14M–$32M; Series B $14M–$37M
- Lead/follow: 55% lead, 45% follow
Portfolio highlights
- Jingling Zhikang — Jingling Zhikang is technology company specializing in the intersection of medical rehabilitation, robotics, and embodied artificial intelligence. The company focuses on developing intelligent rehabilitation bionic hands and upper-limb prosthetics.
- Hanyue New Materials — Hanyue Advanced Materials is a high-tech company that specializes in single-use biopharmaceutical solutions.
- Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfoliosources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Kenya
Investor stats
- Total investments: 103
- Round size: Series A $7.2M–$50M; Series B $15M–$100M; Series C $21M–$128M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — last raise in 2021
Portfolio highlights
- AusperBio — AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
- Shenfu Jianxing — Shenfu Jianxing is a brain-computer interface developer. It focuses on minimally invasive implanted brain-spinal interface technology, with "minimally invasive + low latency + high integration" as its core, to build implantable brain-spinal neural stimulation systems.
- Archimedes Vascular — Archimedes Vascular operates as a medical device company, that treat patients with severe hypertension.
Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB,and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Japan
Investor stats
- Total investments: 623
- Round size: Series A $1.5M–$128M; Series B $10M–$141M; Series C $4.4M–$156M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Prosemi — Pusenmei is a precision micro-resistance current sensor developer company committed to delivering professional and diverse precision micro-resistance current detecting resistors and circuit protection solutions.
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Waker Biology — Weike Bio is a gene therapy drug development company.
ANRI is a Japanese venture capital firm that mainly invests in seed and early-stage startups.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Japan, United States, Indonesia
Investor stats
- Total investments: 311
- Round size: Seed $268k–$9.9M; Series A $967k–$41M; Venture - Series Unknown $616k–$28M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely still investing — raised $102M in 2022
Portfolio highlights
- Any Style — Any Style develops a messaging app from voice actors that regularly sends messages via subscription. It also engages in the planning and production of audio content and the VTuber production business.
- Arrowsmith — Arrowsmith is committed to unlocking the full potential of bacteriophages to revolutionize the treatment of bacterial infectious diseases. Through transformative science, Arrowsmith strive to create a world free from the pain and fear caused by antimicrobial resistance.
- Typewriter Therapeutics — Typewriter Therapeutics, Inc. develops mRNA-based gene therapies using a gene writing, or gene writing, platform for precise insertion of therapeutic genes into the genome. The company builds on transposon-based technologies originating from research by Professor Emeritus Haruhiko Fujiwara at the University of Tokyo. Its programs focus on all‑RNA,nonviral gene writing systems that repurpose natural genetic elements to address severe genetic disorders with limited treatment options. Typewriter Therapeutics conducts research and development across its U.S. and Japan operations and collaborates with investors and partners to advance genetic medicine candidates toward the clinic.
Linear Capital is a Frontier Tech Fund founded in 2014 by Harry Wang, Facebook's first Chinese R&D manager. We currently manage 10 funds with AUM of more than $2 billion.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Manufacturing
- Stage:Seed, Angel, Series A
- Geography: China, Singapore, Switzerland
Investor stats
- Total investments: 94
- Round size: Seed $1.4M–$122M; Angel $1.4M–$122M; Series A $5.7M–$29M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — raised $300M in 2022
Portfolio highlights
- Zhengqi Future — Zhengqi Future focuses on developing embody intelligent robots for a 3km radius living environment.
- Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
- DeepPu Intelligence — DeepPu Intelligence is a high-tech enterprise specializing in the research, development, and innovation of intelligent robotic technologies. The company focuses on creating advanced robotic systems that integrate artificial intelligence, machine vision, and automation to serve a wide range of industries, including manufacturing, logistics,healthcare, and service sectors.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 322
- Round size: Series A $7.1M–$195M; Series B $14M–$141M; Series C $30M–$220M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- VAST — VAST is an artificial intelligence business that develops and manufactures general-purpose 3D big models. Its goal is to develop a popular 3D content production tool, a 3D user-generated content platform, and utilize 3D space to enhance user experience.
- Dingxi Zhichuang — Dingxi Zhichuang is an integrated circuit chip developer specializing in the manufacture, design, and services of integrated circuit chips and products, as well as sales and the manufacturing of semiconductor device special equipment.
- Deep Space Matrix Technology — Deep Space Matrix Technology's long-term objective is to benchmark against SpaceX and progressively construct a Chinese equivalent of an integrated air, space, and sea superintelligent system.
Highlight Capital is an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 179
- Round size: Seed $10M–$84M; Series A $3M–$73M; Series B $7.6M–$70M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $563M in 2021
Portfolio highlights
- Genuine Rhythm — Genuine Rhythm is an innovative AI Agent technology developer specializing in bespoke agent creation, advanced algorithm R&D, and rigorous security compliance solutions tailored to diverse enterprise needs.
- Ziwei Technology — Ziwei Technology is a high-tech company making returnable spacecraft.
- Differential Robotics — Differential Robotics is a robotics company providing research, design, and development of aerial robots and intelligent autonomous drones.
Gaorong Capital is a venture capital firm that focuses on early and growth stage investments in TMT, including AI and frontier technologies.
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 356
- Round size: Seed $2.8M–$100M; Series A $1.6M–$75M; Series B $14M–$120M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — raised $185M in 2022
Portfolio highlights
- Tianji — Tianji develops industrial robotics and intelligent system solutions focused on improving automation in manufacturing environments. The company designs and integrates robot-based systems, including industrial robots, automation equipment, and intelligent production line solutions. It applies technologies such as machine vision, motion control, andedge computing to support tasks like production automation, quality inspection, and logistics handling. Its solutions are used across industries such as manufacturing, healthcare, and new energy to help optimize operational processes and improve safety.
- Cascade — Cascade produces novel medications that target nuclear receptors for treating metabolic disorders and inflammation.
- Inno Medicine — Inno Pharmaceutical Technology specializes in research on the pathogenesis of atherosclerosis. The company focuses on the development of targeted nanoliposomes, targeting molecules with independent intellectual property rights, and currently focuses on the plaque reversal treatment of atherosclerosis.
Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special fundsand have invested 7 billion RMB into 388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises.GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Biotechnology
- Stage:Series A, Angel, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 234
- Round size: Angel $425k–$2.9M; Series A $1.5M–$60M; Series B $3M–$150M
- Lead/follow: 33% lead, 67% follow
- Last fund: Likely actively investing — fresh fund, raised $42M in 2025
Portfolio highlights
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- MirrorSpace — MirrorSpace designs and builds integrated hardware and algorithm software systems for robot spatial perception. The business model focuses on delivering plug-and-play perception modules that save robotics companies from having to integrate raw data from disjointed third-party cameras and LiDAR units internally. By fusing non-visual characteristicslike thermal patterns directly into spatial matrices at the edge, the platform ensures precise data alignment even under harsh environmental blockages. This setup provides physical AI systems with a continuous 4D timeline stream, offering stable environmental input for complex automation tasks.
- Sungen Biomedical — Sungen Biomedical is an innovative antibody drug R&D enterprise. It has established international standard technology platforms and original biological macromolecular R&D pipelines. Their focus includes therapeutic drugs for cardiovascular and cerebrovascular diseases, tumors, and more.
Osaka University Venture Capital is a venture capital firm that focuses on early-stage ventures in the fields of life innovation, green innovation, and platform technology. The firm was founded in 2014 and based in Osaka, Japan.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Japan
Investor stats
- Total investments: 92
- Round size: Seed $480k–$4.5M; Series A $1.5M–$17M; Venture - Series Unknown $685k–$3.5M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $92M in 2021
Portfolio highlights
- JiMED — JiMED designs & develops AI based brain-computer interface for implant in ALS patients to improve communication.
- LQUOM — QWAVE offers cryptography communication technology.
- Toregem BioPharma — Toregem BioPharma is a startup from Kyoto University that develops a treatment for congenital adentia. Toregem BioPharma is headquartered in Kyoto, Japan.
Fast Track Initiative is a venture capital firm with an exclusive focus on life sciences and healthcare services.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: Japan, United States, United Kingdom
Investor stats
- Total investments: 84
- Round size: Seed $345k–$117M; Series A $3M–$51M; Series B $4.7M–$83M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $124M in 2021
Portfolio highlights
- NovAccel — NovAccel operates as a deep tech company, ensure a stable supply of medical radioisotopes.
- Storm Therapeutics — Targeting pathways that modify RNA to deliver novel cancer therapeutics.
- Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Electronics
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, Singapore
Investor stats
- Total investments: 360
- Round size: Seed $1.4k–$14M; Series A $1.6M–$30M; Series B $11M–$48M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — raised $241M in 2021
Portfolio highlights
- Ibeki — Ibeki provides tiny photoelectric displacement sensors and servo control systems. eBridge uses the high precision and miniaturization of its precision motion drive technology to provide customers with a more complete technology portfolio, and has successfully transformed its core technology into a number of military and civilian products,particularly in aerospace, medical equipment, and intelligent control.
- Beta Infinite — Beta Infinite approaches data and model technologies in a distinctive and distinctive way.
- Ruimeng Semiconductor — Ruimeng Semiconductor is a provider of intelligent human-machine interface processor chips and solutions.
TF Capital is a proprietary trading company that specializes in foreign exchange and invests in early stage ventures.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States
Investor stats
- Total investments: 63
- Round size: Series A $10M–$120M; Series B $11M–$110M; Series C $7M–$1.4B
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- QL Biopharma — QL Biopharma focuses on developing innovative drugs and premium me-too drugs targeting metabolic diseases.
- Vivatides Therapeutics — Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research.
- Angitia Biopharmaceuticals — Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases.
ZhenFund is a seed fund founded by former entrepreneurs to invest in the most promising innovators. New Oriental co-founders Bob Xiaoping Xu and Victor Qiang Wang established ZhenFund in 2011 in collaboration with Sequoia Capital China. ZhenFund now has a network of over 800 portfolio companies, including over 30 unicorns based in China. Webelieve that great businesses start with exceptional founding teams. We are dedicated to helping our entrepreneurs build successful companies by providing them with mentorship and the best resources available. Some of our services include biannual demo days to top Chinese VCs, ZhenHR services, marketing and PR consulting, as well as fundraising. Our strong and large CEO network also facilitates entrepreneurs helping each other, especially via our WeChat platform. ZhenFund has been ranked as the “#1 Early-Stage Investment Firm” for six years. Bob Xiaoping Xu, Founder of ZhenFund, has been named on the Midas List since 2016 and ranked #11 in 2019. Anna Fang, Founding Partner and CEO of ZhenFund, has been named on the Midas List since 2019 and made her 4th appearance as #12, and #1 on Midas Seed List in 2022.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, E-Commerce
- Stage:Seed, Series A, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 699
- Round size: Seed $150k–$15M; Angel $425k–$4.2M; Series A $899k–$23M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely still investing — raised $140M in 2022
Portfolio highlights
- Ehang — Ehang is a technology enterprise focused on R&D and production in airplane and aircraft field. With the combination of software and hardware techniques, it self-developed the communication and real-time viewing hardware and a smartphone operation system. Its product, Ghost, is accepted as the first truly smartphone app operated intelligentrobot, which is widely used in geographical information surveying, professional television aerial filming, roadshow displaying, disaster rescuing and delivery, surveillance and monitoring, and even expected to play important role in the future logistics areas.Ehang was founded in 2014 by makers from China, America, and Singapore who are enthusiastic about drone flying. The enterprise’s core members graduated from Tsinghua University, Peking University, and Duke University in America.
- Snowplus — SNOWPLUS is an e-cigarette brand that provides users with e-cigarette products through a combination of online and offline sales models. The products are available in 12 different types of flavors. The products use TrueFeel honeycomb ceramic atomization technology and Aeroflow intake. Technology; In addition to reference to the existing food-gradestandards in China, Xuejia has also passed a number of third-party certifications in terms of safety. The core components such as atomizing core and cigarette holder comply with the highest medical safety standards of the FDA and the European Union.
- Futuring Robot — Futuring Robot is a developer of dual-arm home service robots focusing on C-end home scenarios.
Puhua Capital is an equity investment firm that focuses on early and middle project. Puhua Capital provides the required resources and management experience for the invested enterprise, investing funds and more resources and wisdom. Puhua Capital has invested nearly 300 excellent start-ups.
Show more...Investment focus
- Industry: Health Care, Medical, Manufacturing
- Stage:Series A, Series B, Seed
- Geography: China, United Kingdom, United States
Investor stats
- Total investments: 277
- Round size: Seed $2.3M–$29M; Series A $1.5M–$42M; Series B $3M–$103M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- MindMotion — MindMotion is an electronics company that supplies general-purpose 32-bit MCU products and solutions. The company's MM32 MCU products developed by the company based on the Arm Cortex-M series cores have four series of F/L/SPIN/W, more than 200 models, and a cumulative delivery of more than 300 million units, ranking in theforefront of local general-purpose 32-bit MCU companies.MindMotion was founded in 2011 and is headquartered in Shanghai, China.
- Yitang Technology — Yitang Technology is a developer specializing in high-speed and high-precision placement machines. The company is dedicated to the research and development (R&D) of these advanced machines, as well as the industrialization of intelligent production line solutions.
- Ganzhicao Technology — Gancao Doctor is an internet-based Traditional Chinese Medicine (TCM) company that helps clinics modernize their digital management and optimize operations. By using AI-assisted features, it enhances doctors' diagnostic and treatment abilities, delivering valuable benefits to doctors, patients, and clinics.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies.Hillhouse is a full life-cycle private equityfirm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series B, Series A, Series C
- Geography: China, United States, Singapore
Investor stats
- Total investments: 331
- Round size: Series A $2.9M–$165M; Series B $15M–$230M; Series C $15M–$220M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — raised $11B in 2018
Portfolio highlights
- Sainte — Sainte is a company which provides professional nutritional solutions for babies with different nutritional needs
- Vita Dynamics — Vita Dynamics involves learning through real-world interactions by developing robots that can physically engage with their environment, they can adapt more naturally and efficiently.
- NeueHCT — Horizon Continental Technology is a joint venture between Continental Group and Horizon Robotics
Founded in 2011, Delian Capital specializes in the field of tech-driven industry such as high-end manufacturing, cutting-edge technologies, and healthcare. Their investments range from robotics, Smart manufacturing Semiconductor, AI, big data, enterpriseservices, healthcare, etc.Examples of their investment portfolio: YueBoo、Hunan zhongli、Esafenet、Venus MedTech、MicuRx、Rokae、 IMI、12 Sigma Technologies.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Health Care
- Stage:Series A, Seed, Series B
- Geography: China, United States, France
Investor stats
- Total investments: 100
- Round size: Seed $1.5M–$50M; Series A $1.6M–$20M; Series B $9.9M–$30M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- GeneMind Biosciences — GeneMind Biosciences is a domestic third-generation single-molecule gene sequencing system. GeneMind Biosciences has been fighting to provide better gene sequencing solutions for clinicians and researchers. A Gene sequencer is the crown jewel in the field of gene sequencing. Entrepreneurs will lead their innovations and breakthroughs throughunremitting research and exploration. GeneMind believes that the strong pass of the difficulty is like a wall of iron, yet with firm strides, we are conquering its summit.
- Micronano Core — Micro-nano core is committed to the development and production of the world's leading intelligent IoT AIoT SoC serialized chips, through the world's leading four core technologies: ultra-low-power chip architecture technology (to solve the problem of system standby power consumption), ultra-low power consumption Power consumptionclosed-loop adaptive near-threshold circuit technology (to solve the problem of chip running power consumption), ultra-low power consumption and high-precision sensor acquisition technology (to solve the problem of high precision and low power consumption of sensor signal acquisition) and high-efficiency embedded AI engine technology (solving the computing power and energy efficiency of embedded AI), creating a general/platform technology system for IoT chips and AIoT serialized chips, enabling IoT products, and significantly improving the low power consumption, low power consumption, and low power consumption of future IoT products High-precision detection and edge AI inference performance.
- Yanhe Technology — Yanhe Technology provides solar power generation technology-related services.
Panlin Capital, following the investment theme of ‘consumption upgrade driven by technology innovation’, targets the start-ups which are specialized in biotechnology and data intelligence sectors.As a venture capital corporation, Panlin Capital has became professional as well as influential in the biotechnology and data intelligence sectors.Identify the entrepreneurs among scientists.Enable the innovators among entrepreneurs。
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 83
- Round size: Seed $1.4k–$28M; Series A $297k–$37M; Series B $7.3M–$58M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Lingdong Core Optics — Lingdong Core Optics is a high-tech firm that specializes in the design and implementation of silicon-based integrated optoelectronic chips.
- UniXell Biotechnology — Yuesai Biotechnology is a new-generation cell therapy drug developer, focusing on the development of a new generation of cell therapy drugs.
- Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 354
- Round size: Seed $1.4M–$20M; Series A $4M–$76M; Series B $7.2M–$50M
- Lead/follow: 45% lead, 55% follow
- Last fund: May invest from a new fund soon — raised $75M in 2014
Portfolio highlights
- Bytetree — Bytetree is a technology company that focuses on providing the one-stop AI data services for data collection, cleaning, labeling, management, and storage for OEMs and autonomous driving solution providers, covering bicycle intelligence. , vehicle-road coordination, and smart cockpit three scenarios.
- Digital China — Digital China is a robotics company focused on developing humanoid interactive robots that can break traditional boundaries and create emotionally resonated partners.
- Kiri Innovation — KIRI Innovation develops affordable and innovative 3D scanners. Phiz 3D Scanner is a low cost, high precision laser 3D scanner that works with smartphones. Using today's phone camera and powerful CPU, a laser 3D scanner has never been so affordable and smart.
UTEC-The University of Tokyo Edge Capital Partners Co., Ltd.. UTEC is a seed/early stage technology focused venture capital firm associated with The University of Tokyo.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Series B
- Geography: Japan, United States, India
Investor stats
- Total investments: 209
- Round size: Seed $900k–$14M; Series A $2.3M–$18M; Series B $2.8M–$20M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely actively investing — fresh fund, raised $326M in 2025
Portfolio highlights
- Mujin — At Mujin, we design automation platforms to enhance any robot, enable advanced capabilities and lower operating costs.
- Sinumy — Sinumy develops touchless identity authentication technology and high-speed, high-precision position measurement technology.
- X Mile — Corporate Site:https://www.xmile.co.jp/ Service Site:https://x-work.jp/
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 82
- Round size: Seed $2.5M–$14M; Series A $3M–$28M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Shengxin Medical — Shengxin Medical is a cardiovascular interventional medical device developer, dedicated to creating innovative, high-quality solutions that improve the diagnosis, treatment, and management of cardiovascular diseases, while advancing minimally invasive medical technologies to enhance patient outcomes and clinical efficiency.
- Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
- Kingsung Medical Group — Kingsung Medical Group operates under the Mission “Simplify Surgery, Beautiful Life,” with its innovation centered on four core technology platforms at its Tianjin base: Mechanical Design, Polymer Materials, Biodegradable Magnesium Alloys, and Collagen Biomaterials. These platforms have enabled the development of pioneering medical devices,including microvascular anastomosis devices and neural tube. In particular, the Group’s biodegradable magnesium alloy technology is spearheading the advancement of next-generation orthopedic implants. Kingsung’s technological capabilities are evidenced by a portfolio of over 190 patents and its recognition as a National Key Enterprise. The Group also actively contributes to the industry as a standing council member of the Microsurgery Branch of the China Association of Medical Devices Industry and a member of the Chinese Society for Biomaterials.
Beijing Huafang Investment focuses on the investment and management of state-owned capital and its investment covers commercial real estate.
Show more...Investment focus
- Industry: Biotechnology, Medical, Biopharma
- Stage:Series A, Seed, Angel
- Geography: China
Investor stats
- Total investments: 27
- Round size: Seed $13M–$14M; Series A $14M–$30M
- Lead/follow: 41% lead, 59% follow
Portfolio highlights
- ClonOrgan — ClonOrgan has developed a technology to humanize pig cells that will grow into human-compatible organs.The business specializes in xenotransplantation and has a one-stop R&D platform that includes raising gene-edited pigs, preclinical testing, and breeding. It is dedicated to addressing the critical shortage of clinical organ transplantationand creating the organ factory of the future.ClonOrgas was established in 2005 in Chengdu, Sichuan.
- Glimmer Gene — Glimmer Gene develops a comprehensive gene editing and epigenetic toolkit with independent intellectual property rights.
- Kaiwang Data — Kaiwang Data is a one-stop shop for data solutions. It focuses on offering complete data labeling solutions for automakers and businesses involved in autonomous driving.
Shenzhen Oriental Fortune Capital Co Ltd. is a venture capital firm specializing investment in early venture, mid venture, late venture, emerging growth, Pre-IPO, mature, growth capital stage, mezzanine and new third board investments. The firm typically invests in financial services, telecommunication, new energy, consumer goods, medical treatmentand healthcare, life sciences, internet plus healthy lifestyle industry, logistics, energy technology, information technology, mobile innovation, media, movies and television, culture, pharmaceutical, biological medicine, renewable energy, retail, environmental protection business, consumption, new materials, new agriculture, advanced manufacturing, equipment manufacturing, culture, entertainment, and services. It seeks to invest in China focusing on Shenzhen, Shanghai, Beijing, Xi’an, and Wuhu. The firm also invests in Pearl River Delta region, Yangtze River Delta region, and Circum-Bohai-Sea region. For Pearl River Delta, it covers Guangzhou, Shenzhen, Foshan, Dongguan, Zhongshan, Zhuhai, Huizhou, Jiangmen, and Zhaoqing cities in China. For Yangtze River Delta, the firm covers Shanghai, Nanjing, Wuxi, Changzhou, Suzhou, Nantong, Yancheng, Yangzhou, Zhenjiang, Taizhou, Hangzhou, Ningbo, Jiaxing, Huzhou, Shaoxing, Jinhua, Zhoushan, Taizhou, Hefei, Wuhu, Ma’anshan, Tongling, Anqing, Chuzhou, Chizhou, and Xuancheng cities in China. For the Circum-Bohai-Sea region, it covers Beijing, Tianjin, Shenyang, Dalian, Qingdao, Dandong, Yingkou, Panjin, Fuxin, Huludao, Chaoyang, Shijiazhuang, Baoding, Tangshan, Qinhuangdao, Cangzhou, Langfang, Chengde, Zhangjiakou, Handan, Xingtai, Dongying, Yantai, Weifang, Weihai, Rizhao, and Binzhou cities in China. The firm prefers to invest 20% of its portfolio to early stage, 40% to expansion stage, and 40% to Pre-IPO stage. Shenzhen Oriental Fortune Capital Co Ltd. was formed in November 2007 and is based in Shenzhen, China with offices in Shanghai, China; Beijing, China; and Wuhu, China.
Show more...Investment focus
- Industry: Software, Manufacturing, Information Technology
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 323
- Round size: Seed $1.5M–$100M; Series A $1.4M–$30M; Series B $3.2M–$100M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Memory tensor — Memory tensor designed with a focus on systematic innovation, grounded firmly in fundamental principles, serves as a powerful tool for scalable and adaptable intelligence. Its architecture emphasizes three core attributes: low cost, ensuring economic feasibility and accessibility; low illusion, reducing overfitting and minimizing hallucinations ormisleading outputs; and high generalization.
- Ziwei Technology — Ziwei Technology is a high-tech company making returnable spacecraft.
- Lightwheel — Light Wheel Intelligence is offers automated, physically precise and controllable, real and generalizable synthetic data solutions to build AI data infrastructure,
CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 73
- Round size: Seed $1.4M–$15M; Series A $1.5M–$32M; Series B $7.6M–$34M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Genlight — Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.
- Pipi Bear — Pipi Bear is a creator of living robots and health goods, with a focus on those that improve the lives of the elderly.
- CORE Biomedicine — CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology.
Legend Star helps entrepreneurs create great businesses through investments, CEO training sessions and an entrepreneurs alliance.Since 2008, Legend Star has incubated and invested in nearly 600 companies and is deeply integrated in the Chinese entrepreneurial ecosystem.Legend Star is the independent early-stage investment arm of LegendHoldings. Legend Holdings is the parent company of Lenovo, Raycom Real Estate, Joyvio Agribusiness and a large range of fast-growing Chinese companies.
Show more...Investment focus
- Industry: Health Care, Medical, Robotics
- Stage:Series A, Seed, Angel
- Geography: China, United States, France
Investor stats
- Total investments: 168
- Round size: Seed $1.5M–$19M; Angel $425k–$49M; Series A $1.5M–$52M
- Lead/follow: 23% lead, 77% follow
- Last fund: May invest from a new fund soon — raised $127M in 2018
Portfolio highlights
- CellWall — Cellwall is a desktop robot developer focused on the research, development, upgrade, and marketing of its initial product, CyboPal ONE.
- Ubot Robotics — Ubot Robotics is dedicated to developing leg-and-foot bionic robots and has built a diverse range of bipedal, quadrupedal, hexapodal, and other leg-and-foot bionic robots.
- Active Technology — Active Technology is a pioneering deep tech startup specialized in developing invasive brain computer interface (BCI) technology. The company integrates flexible electrodes, dedicated chips, and advanced decoding algorithms to target motor, visual, and emotional neural pathways.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Keio Innovation Initiative (KII) is a venture capital established by Keio University. In order to make more effective use of the research results of Keio University, we aim to contribute to the development of society by creating investment for venture companies that utilize research results and creating new industries.The key to thinking aboutJapan's future growth strategy is to utilize advanced research results of the university. In addition to GDP, in addition to GDP, Japan is the world's third largest R & D exporter in R & D expenses, but as the low growth rate shows, it has a problem in investment efficiency in research and development. There are also reports on the entrepreneurial spirit that is indispensable for creating new industries, with the lowest entrepreneurial activity rate among developed countries.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Venture - Series Unknown
- Geography: Japan, United Kingdom
Investor stats
- Total investments: 91
- Round size: Seed $826k–$14M; Series A $2.2M–$41M; Venture - Series Unknown $1.6M–$12M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $94M in 2020
Portfolio highlights
- ElleThermo — elleThermo aims to implement Semiconductor-Sensitised Thermal Cells (STCs), an energy conversion technology that can generate electricity from unused waste heat above room temperature.
- Starlight Engine — Starlight Engine develops and commercializes fusion energy power plant technologies.
- Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Mizuho is the venture capital firm affiliated to Mizuho Bank, the second-largest Japanese bank in terms of assets. The firm has headquarters in Tokyo.The firm has ¥49.6 billion JPY under management, focusing on information technology and biotechnology investments. Over 600 Mizuho companies have gone public. According to Nikkei, Mizuho is thefifth-largest venture capital firm in Japan.Mizuho Capital was formed in 2002 by the merger of Fujigin Capital, Tokyo Venture Capital and IBJ Investment. Three firms were subsidiaries of Fuji Bank, Dai-Ichi Kangyo Bank and the Industrial Bank of Japan respectively.
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Series A, Venture - Series Unknown, Series B
- Geography: Japan, United States, Singapore
Investor stats
- Total investments: 537
- Round size: Series A $1.4M–$41M; Series B $2.4M–$47M; Venture - Series Unknown $661k–$11M
- Lead/follow: 5% lead, 95% follow
- Last fund: May invest from a new fund soon — raised $92M in 2020
Portfolio highlights
- CaTe — CaTe is based in Tokyo. CaTe develops and manufactures a Digital Therapeutic (DTx) for remote cardiac rehabilitation. Their invention allows heart disease patients to safely and successfully complete cardiac rehabilitation utilizing standing exercise in a confined space, such as at home, without the use of ergometers or similar instruments.
- Paytner — Paytner is providing services to support freelance people's funding. The freelance population in Japan has been shown to continue to increase in many Chosa. While working styles are diversified, they are not able to respond to the development of the working environment, and they will develop their business to change the situation whereproblems such as funding, credit, sexual harassment, and power harassment are accumulated.
- Power Laser — Power Laser is a startup company that offers a range of power laser technologies and applications. The company develops high-power laser systems, related components, and software for advanced industrial and scientific applications. Its mission, “Power lasers open the future,” reflects its focus on next-generation photonics and precision laserinnovation for manufacturing and research sectors.
K2VC (Xianfeng Evergreen) was founded in 2010, focused on early stage investment in technology start-ups in China, focus on promoting change and technological progress, innovative business models and lifestyles.
Show more...Investment focus
- Industry: E-Commerce, Manufacturing, Software
- Stage:Series A, Angel, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 298
- Round size: Seed $1.4M–$14M; Angel $356k–$5M; Series A $1.4M–$38M
- Lead/follow: 23% lead, 77% follow
- Last fund: Likely actively investing — fresh fund, raised $31M in 2025
Portfolio highlights
- Quantex — Quantex is committed to focusing on the next generation of information technology and integrated circuit fields, and is dedicated to the in-depth research and development of 3.2T/6.4T photonic integrated chips (PIC), optical modules and CPO (co-packaged optics) solutions, leading the localization of high-end optical transmission chips.
- XinYang Micro — Xinyangwei is an early stage underwater sensing chip startup specializing in CMUT (Capacitive Micromachined Ultrasonic Transducer) technology. The company provides integrated acoustic sensing modules and 3D imaging components designed to give pool cleaning robots intelligent near field path planning and mapping capabilities.
- ChipSense Technology — ChipSense Technology is a semiconductor focused on developing high-performance chips for AI computing infrastructure. The company provides chip solutions that enable perception and efficiency management in AI computing centers, helping optimize resource utilization, operational efficiency, and intelligent management of large-scale AI computingclusters.
Doma Protocol is a purpose-built blockchain to modernize and unlock the liquidity of over 362M existing and future domains
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, United States, Singapore
Investor stats
- Total investments: 243
- Round size: Seed $1.9M–$28M; Series A $1.5M–$43M; Series B $8M–$123M
- Lead/follow: 22% lead, 78% follow
- Last fund: Likely still investing — raised $141M in 2023
Portfolio highlights
- Sondit — Sondit specializes in R&D and manufacturing of civilian radar systems. It includes intelligent transportation, intelligent security, vehicle-road coordination, and other fields. It engaged in traffic information monitoring and urban traffic management in the field of the intelligent transportation industry.
- Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
- Differential Robotics — Differential Robotics is a robotics company providing research, design, and development of aerial robots and intelligent autonomous drones.
Shunwei Capital is a venture capital fund that focuses on early to mid-stage investments in local internet industry. It specializes in incubation, startups, early to mid-stage, and growth capital investments. It seeks to invest in the technology, media, telecommunications, high technology, new media, games, internet finance, and rural area internetsectors. Their investors include sovereign wealth funds, fund of funds, university endowment funds, and family offices.
Show more...Investment focus
- Industry: Manufacturing, Software, Internet
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 600
- Round size: Series A $1.5M–$35M; Series B $8.2M–$50M; Series C $20M–$105M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2018
Portfolio highlights
- uban — Uban provides an internet office leasing and trading services platform that helps to connect owners, customers and brokers, corporate customers in order to provide office rental and follow-up services, enabling its clients to receive real estate related services through a single portal. The company is based in Beijing, China.
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- Deepin kernel — Deep Kernel offers customizable AI infrastructure and core-engine services to businesses.
Since its founding in 1973, JAFCO has always worked with leading-edge entrepreneurs. The total capital commitments of its investment funds in Japan and overseas have exceeded 1 trillion yen and the number of portfolio IPOs to date has reached over 1,000. In addition to venture investment, JAFCO also carries out buyout investment and commit to thecreations of innovative technologies and services worldwide. As entrepreneurs’ closest partner in bringing their visions to life, JAFCO provides support in areas of HR, marketing/ sales, and back-office operations, in addition to providing financing.
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: Japan, United States, Israel
Investor stats
- Total investments: 337
- Round size: Series A $2.4M–$71M; Series B $5M–$36M; Venture - Series Unknown $1.3M–$27M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $567M in 2019
Portfolio highlights
- ADiXi — Adixi is a tech-driven business that supports the idea that people and technology may work together. It strives to open doors by utilizing cutting-edge technology, such as artificial intelligence, to promote long-term, sustainable corporate and societal progress.
- EISHIN — EISHIN is a technology company that specializes in pet tech business, recruitment consulting, website creation, and development services.
- Yokohama Vanilla — Yokohama Vanilla is a Company which operates Yokohama-based gift sweets brand.
BioTrack Capital invests in early and growth stage companies within life sciences, healthcare technology, biotechnology and related high-tech sectors, providing capital and investment support for innovation. The firm evaluates scientific and commercial potential of ventures and structures financings aimed at advancing technologies from earlyresearch to market engagement. Its activities include sourcing opportunities, conducting due diligence, and working with founders and management teams to align growth strategies with investor objectives. BioTrack Capital also participates in funding rounds alongside co-investors to support development of novel healthcare and tech solutions. The company engages with portfolio companies through strategic interaction and monitoring of progress toward business milestones.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 94
- Round size: Seed $15M–$168M; Series A $14M–$45M; Series B $15M–$147M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Taiyi Quantum — Taiyi Quantum is dedicated to encouraging innovation in the distribution and implementation of quantum computing technology, as well as developing sophisticated quantum algorithms and delivering tailored computing solutions for businesses and research institutes.
- Convergen — Convergen develops TrimTAC, a targeted protein degradation platform for treating neurodegenerative diseases and other conditions driven by protein aggregates
- Zhiyue Space Intelligence — Zhiyue Space Intelligence specializes in robotic brain and brain systems.
Hillhouse Venture Capital is an investment institution established by Hillhouse Capital that focuses on investing in early-stage startups.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Health Care
- Stage:Series A, Series B, Seed
- Geography: China, Singapore, Norway
Investor stats
- Total investments: 77
- Round size: Seed $10M–$120M; Series A $10M–$85M; Series B $14M–$99M
- Lead/follow: 44% lead, 56% follow
Portfolio highlights
- Yatsen Holding — Yasten provides high-quality fashion makeup products.
- kaye technology — Kaye Technology is a company that provides automation upgrade solutions for beverage equipment.
- Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
ounded in 2016, SDIC Venture Capital Co., Ltd. (SDICVC) is a fund management company founded by the State Development and Investment Corp. (SDIC), under a market driven governance structure. SDICVC currently manages four funds, with total asset under management at RMB 14 Billion.SDICVC puts into practice the marketization and industrializationof the nation’s scientific and technological achievements, focusing on an investment strategy of "serving the national innovation strategy and focusing on the transformation of scientific and technological achievements". SDICVC puts its expertise and experience to work to achieve its goals of policy orientation and return on investment, faithfully implementing the national development strategy, striving to realize the synergy between the government, the society and the market, realizing its positioning as "an ideal, trustworthy, respected, influential partner” and its role as a leading professional venture fund management institution.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Electronics
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 166
- Round size: Series A $8.5M–$100M; Series B $2.8M–$129M; Series C $14M–$58M
- Lead/follow: 54% lead, 46% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Parylene — Parylene is a provider of protective coating application solutions
- Alnan Aluminium — Professional aluminium profile manufacturer from China, offering quality aluminium profile with reasonable price.
- Huaguan Biotechnology — Huaguan Biotechnology provides high-quality integrated drug research and development services for customers. This includes Sihuan Pharmaceutical, Sichuan Kelun, Tianjin Tasly, Beijing Yabao, Huasu Pharmaceutical, and other well-known domestic pharmaceutical companies, as well as Suzhou Amate, Shanghai Fuqi, Jiangsu Ya Sheng, and other scientificand technological innovation enterprises, the team development ability has been recognized by the industry and has attracted a number of listed companies such as Sihuan Pharmaceutical to inject capital.
Taiyu Investment is an investment firm.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed, Series A, Angel
- Geography: China
Investor stats
- Total investments: 43
- Round size: Seed $4.1M–$20M; Series A $13M–$29M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Immunocan — JAWA138 memimpin di garis depan Inovasi Sistem Permainan Digital dengan fokus pada transparansi dan keadilan, terutama melalui Mekanisme RTP (Return to Player) yang Akurat.
- Rhino Medical — Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments
- Infineon Multiomics — Infineon Multiomics is a biotechnology company that provides research and application of space multiomics technology.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in Asia investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 investors investing in Asia Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!